Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Issue: May/Jun 2020 - Volume 24, Number 3
View All Articles in Issue
Page(s): 194-197
Note: Electronic version includes supplemental material.
Download in electronic PDF format for $75
Abstract: Beta blockers (timolol 0.5% ophthalmic solution) delivered topically to the eyes or sublingually have recently been reported in case series and small placebo controlled studies to be effective in some cases of acute migraine. Rapid systemic absorption to achieve therapeutic levels of beta blockers is extremely important in the treatment of acute migraine. Nasal delivered beta blockers have been shown to be absorbed as fast as intravenous administration and seem ideal for acute migraine treatment. A nasal delivered beta-blocker spray has not been available. In 2019, O’Brien Pharmacy prepared a compounded timolol nasal spray that is now available to authorized prescribers. The theoretical basis for using nasal beta blocker spray is presented and research on fast-acting beta-blocker solutions for acute migraine is reviewed.
Related Keywords:
acute migraine, beta-blockers, beta-adrenergic antagonists, timolol eye drops, nasal spray, intranasal administration, formulation, Mucolox gel, beta blockade contraindications
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III, Everett Eric, Chamberlain Tyler
|
May/Jun 2020
Pg. 194-197
|
Addendum to Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine A New Therapeutic Modality
|
Mar/Apr 2024
Pg. 129
|
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
|
Sep/Oct 2022
Pg. 364-368
|
Timolol 0.125%/Mucolox 15%/0.9% Normal Saline Nasal Spray
Allen Loyd V Jr
|
Mar/Apr 2023
Pg. 153
|
Acute Migraine Treatment with Timolol 0.5% Nasal Spray - Compounding Pharmacists Have an Important Role
Hagan John C III, Kosa Steven C, Chamberlain Tyler
|
Jul/Aug 2024
Pg. 286-290
|
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
|
Jul/Aug 2016
Pg. 328-332
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Choo Winnie
|
Jul/Aug 2017
Pg. 282-289
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
A Concise Discussion of Headache Types, Part 3: Migraine
Williams LaVonn A, Allen Loyd V Jr
|
Jul/Aug 2012
Pg. 270-274
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Compounding with Beta-1, 3-D-Glucan
Keller Ted
|
Sep/Oct 2000
Pg. 342
|
Sumatriptan 5-mg or 20-mg per 100-μL Nasal Spray
Allen Loyd V Jr
|
Mar/Apr 2016
Pg. 147
|
Prochlorperazine Edisylate 0.5% Nasal Spray
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 150
|
Ipratropium Bromide 0.05% Nasal Spray
Allen Loyd V Jr
|
Sep/Oct 2023
Pg. 418-419
|
Sodium Citrate 9% Nasal Spray for Olfactory Disorders
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 57
|
Dexpanthenol 5% Nasal Spray
Allen Loyd V Jr
|
May/Jun 2016
Pg. 229
|
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William, Angelle Patricea (Patsy), Chang Richard I
|
Nov/Dec 2009
Pg. 506-515
|
Labetalol 50-mg Capsules
Allen Loyd V Jr
|
May/Jun 2013
Pg. 233
|
Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2018
Pg. 233
|
| Return to Top |
